Filing Details
- Accession Number:
- 0001072613-18-000203
- Form Type:
- 13G Filing
- Publication Date:
- 2018-03-09 17:26:48
- Filed By:
- Arch Venture Fund Vii Lp
- Company:
- Juno Therapeutics Inc. (NASDAQ:JUNO)
- Filing Date:
- 2018-03-09
- SEC Url:
- 13G Filing
Filing
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 4)*
| Juno Therapeutics, Inc. |
| (Name of Issuer) |
| |
| Common Stock |
| (Title of Class of Securities) |
| |
| 48205A109 |
| (CUSIP Number) |
| |
| March 5, 2018 |
| (Date of Event Which Requires Filing of this Statement) |
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
☐ Rule 13d-1(b)
☐ Rule 13d-1(c)
☒ Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes).
| CUSIP No. 48205A109 | 13G | Page 2 of 6 Pages |
| Item 1(a). | Name of Issuer |
Juno Therapeutics, Inc. (the "Issuer").
| Item 1(b). | Address of Issuer's Principal Executive Offices |
400 Dexter Avenue North, Suite 1200, Seattle, WA 98109
| Item 2(a). | Name of Person Filing |
ARCH Venture Fund VII, L.P. ("ARCH Venture Fund VII"); ARCH Venture Partners VII, L.P. ("AVP VII LP"); ARCH Venture Partners VII, LLC ("AVP VII LLC") (collectively, the "Reporting Entities" and individually, each a "Reporting Entity"); and Keith Crandell ("Crandell"), Robert Nelsen ("Nelsen") and Clinton Bybee ("Bybee") (collectively, the "Managing Directors" and individually, each a "Managing Director"). The Reporting Entities and the Managing Directors collectively are referred to as the "Reporting Persons".
| Item 2(b). | Address of Principal Business Office or, if none, Residence |
8755 W. Higgins Avenue, Suite 1025, Chicago, IL 60631
| Item 2(c). | Citizenship |
ARCH Venture Fund VII and AVP VII LP are limited partnerships organized under the laws of the State of Delaware. AVP VII LLC is a limited liability company organized under the laws of the State of Delaware. Each Managing Director is a US citizen.
| Item 2(d). | Title of Class of Securities |
Common stock, par value $0.0001 per share.
| Item 2(e). | CUSIP Number |
48205A109
| Item 3. | If This Statement Is Filed Pursuant to Sections 240.13d-1(b) or 240.13d-2(b) or (c), Check Whether the Person Filing Is a(n): |
Not Applicable.
| Item 4. | Ownership |
Not Applicable.
| Item 5. | Ownership of Five Percent or Less of a Class |
Each of the Reporting Persons has ceased to beneficially own five percent (5%) or more of the Issuer's outstanding Common Stock.
| CUSIP No. 48205A109 | 13G | Page 3 of 6 Pages |
| Item 6. | Ownership of More Than Five Percent on Behalf of Another Person |
Not Applicable.
| Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company |
Not Applicable.
| Item 8. | Identification and Classification of Members of the Group |
Not Applicable.
| Item 9. | Notice of Dissolution of Group |
Not Applicable.
| Item 10. | Certification |
Not Applicable.
| CUSIP No. 48205A109 | 13G | Page 4of 6 Pages |
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Dated: March 9, 2018
| ARCH VENTURE FUND VII, L.P. | |
| By: ARCH Venture Partners VII, L.P. | |
| its General Partner |
| By: ARCH Venture Partners VII, LLC | |
| its General Partner |
| By: * | |
| Keith Crandell | |
| Managing Director |
| ARCH VENTURE PARTNERS VII, L.P. | |
| By: ARCH Venture Partners VII, LLC | |
| its General Partner |
| By: * | |
| Keith Crandell | |
| Managing Director |
| ARCH VENTURE PARTNERS VII, LLC | |
| By: * | |
| Keith Crandell | |
| Managing Director |
| * | |
| Keith Crandell |
| * | |
| Robert Nelsen |
| * | |
| Clinton Bybee |
| * By: /s/ Mark McDonnell | ||
| Mark McDonnell as | ||
| Attorney-in-Fact |
This Amendment No. 4 to Schedule 13G was executed by Mark McDonnell pursuant to Powers of Attorney attached hereto as Exhibit 2 and incorporated herein by reference.
| CUSIP No. 48205A109 | 13G | Page 5 of 6 Pages |
Exhibit 1
AGREEMENT
Pursuant to Rule 13d-1-(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of shares of stock of Juno Therapeutics, Inc.
This Agreement may be executed in any number of counterparts, each of which shall be deemed an original.
| Dated: March 9, 2018 | ARCH VENTURE FUND VII, L.P. |
| By: ARCH Venture Partners VII, L.P. | |
| its General Partner |
| By: ARCH Venture Partners VII, LLC | |
| its General Partner |
| By: * | |
| Keith Crandell | |
| Managing Director |
| ARCH VENTURE PARTNERS VII, L.P. | |
| By: ARCH Venture Partners VII, LLC | |
| its General Partner |
| By: * | |
| Keith Crandell | |
| Managing Director |
| ARCH VENTURE PARTNERS VII, LLC | |
| By: * | |
| Keith Crandell | |
| Managing Director |
| * | |
| Keith Crandell |
| * | |
| Robert Nelsen |
| * | |
| Clinton Bybee |
| * By: /s/ Mark McDonnell | ||
| Mark McDonnell as | ||
| Attorney-in-Fact |
This Agreement was executed by Mark McDonnell pursuant to Powers of Attorney attached hereto as Exhibit 2 and incorporated herein by reference.
| CUSIP No. 48205A109 | 13G | Page 6 of 6 Pages |
Exhibit 2
POWERS OF ATTORNEY
KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Mark McDonnell his true and lawful attorney-in-fact, with full power of substitution, to sign any and all instruments, certificates and documents that may be necessary, desirable or appropriate to be executed on behalf of himself as an individual or in his capacity as a direct or indirect general partner, director, officer or manager of any partnership, corporation or limited liability company, pursuant to section 13 or 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and any and all regulations promulgated thereunder, and to file the same, with all exhibits thereto, and any other documents in connection therewith, with the Securities and Exchange Commission, and with any other entity when and if such is mandated by the Exchange Act or by the Financial Industry Regulatory Authority, granting unto said attorney-in-fact full power and authority to do and perform each and every act and thing necessary, desirable or appropriate, fully to all intents and purposes as he might or could do in person, thereby ratifying and confirming all that said attorney-in-fact, or his substitutes, may lawfully do or cause to be done by virtue hereof.
IN WITNESS WHEREOF, this Power of Attorney has been signed as of the 7th day of May, 2013.
| ARCH VENTURE FUND VII, L.P. | |
| By: ARCH Venture Partners VII, L.P. | |
| its General Partner |
| By: ARCH Venture Partners VII, LLC | |
| its General Partner |
| By: /s/ Keith Crandell | |
| Managing Director |
| ARCH VENTURE PARTNERS VII, L.P. | |
| By: ARCH Venture Partners VII, LLC | |
| its General Partner |
| By: /s/ Keith Crandell | |
| Managing Director |
| ARCH VENTURE PARTNERS VII, LLC | |
| By: /s/ Keith Crandell | |
| Managing Director |
| /s/ Keith Crandell | |
| Keith Crandell |
| /s/ Robert Nelsen | |
| Robert Nelsen |
| /s/ Clinton Bybee | |
| Clinton Bybee |